NCCN VERSION 2 2015

154 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-79
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
with HER2-positive early breast cancer: a randomized phase II cardiac
safety study (TRYPHAENA). Ann Oncol 2013;24:2278-2284. Available
at:
169. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of
neoadjuvant pertuzumab and trastuzumab in women with locally
advanced, inflammatory, or early HER2-positive breast cancer
(NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Lancet Oncol 2012;13:25-32. Available at:
.
170. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective
neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-
2-positive, estrogen receptor-positive primary breast cancer: evidence
from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
Available at: .
171. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of
postmenopausal breast cancer with anastrozole, tamoxifen, or both in
combination: the Immediate Preoperative Anastrozole, Tamoxifen, or
Combined with Tamoxifen (IMPACT) multicenter double-blind
randomized trial. J Clin Oncol 2005;23:5108-5116. Available at:
.
172. Hellman S. Stopping metastases at their source. N Engl J Med
1997;337:996-997. Available at:
173. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative
radiotherapy in high-risk premenopausal women with breast cancer who
receive adjuvant chemotherapy. Danish Breast Cancer Cooperative
Group 82b Trial. N Engl J Med 1997;337:949-955. Available at:
174. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative
radiotherapy in high-risk postmenopausal breast-cancer patients given
adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG
82c randomised trial. Lancet 1999;353:1641-1648. Available at:
.
175. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation
therapy in patients with high-risk breast cancer receiving adjuvant
chemotherapy: 20-year results of the British Columbia randomized trial.
J Natl Cancer Inst 2005;97:116-126. Available at:
.
176. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy:
clinical practice guidelines of the American Society of Clinical Oncology.
J Clin Oncol 2001;19:1539-1569. Available at:
.
177. Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation
improves local-regional control and survival for selected patients with
locally advanced breast cancer treated with neoadjuvant chemotherapy
and mastectomy. J Clin Oncol 2004;22:4691-4699. Available at:
.
178. McGuire SE, Gonzalez-Angulo AM, Huang EH, et al.
Postmastectomy radiation improves the outcome of patients with locally
advanced breast cancer who achieve a pathologic complete response
to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys
2007;68:1004-1009. Available at:
.
179. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of
postmastectomy irradiation limited to patients with four or more positive
nodes, as recommended in international consensus reports? A
subgroup analysis of the DBCG 82 b&c randomized trials. Radiother
Oncol 2007;82:247-253. Available at:
.
180. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of
hypofractionated radiation therapy for breast cancer. N Engl J Med
2010;362:513-520. Available at:
.